Scarica l'app Stockscreener
8.61
4.87%
0.40
Pre-mercato:
8.49
-0.12
-1.39%
Armata Pharmaceuticals Inc Borsa (ARMP) Ultime notizie
ARMP Reports Decrease in Grant Revenue for Q4 2025 - GuruFocus
Armata Pharmaceuticals: Advancing Bacteriophage Therapies for Antibiotic-Resistant Bacterial Infections in 2025 - Minichart
Armata Pharmaceuticals (ARMP) Q4 and Full-Year 2025 Earnings: Revenue Beat, Net Loss Hits $173.8M - Bayelsa Watch
Breakout Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stockPrice Action & AI Powered Market Trend Analysis - baoquankhu1.vn
ARMATA PHARMACEUTICALS, INC._December 31, 2025 - SEC.gov
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - PR Newswire
ARMP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Armata Pharmaceuticals Reports Positive Phase 2a Study Results - MSN
HC Wainwright reaffirms buy on Armata Pharmaceuticals, Inc. (ARMP) after FDA nod - MSN
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval By Investing.com - Investing.com India
Armata Pharmaceuticals (ARMP) Delays Financial Results Release - GuruFocus
Armata Pharmaceuticals delays announcement of fourth quarter and full-year 2025 results and provides corporate update - marketscreener.com
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval - Investing.com
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - Finviz
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay - TipRanks
Armata Pharmaceuticals delays 2025 results, wins QIDP and readies Phase 3 for AP-SA02 - TradingView
Armata Pharmaceuticals (ARMP) delays 2025 results, advances AP-SA02 toward Phase 3 - Stock Titan
Armata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan
شركة أرماتا للأدوية تؤجل الإعلان عن نتائج الربع الرابع والعام 2025 بالكامل، وتقدم تحديثاً عن الشركة. - Sahm
Armata Pharmaceuticals (ARMP) CBO reports tax-withheld share disposition - Stock Titan
Armata (ARMP) CEO Birx has 4,919 RSU shares withheld for tax obligations - Stock Titan
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Thursday - MarketBeat
Director at Armata (NASDAQ: ARMP) receives 25,640 stock options grant - Stock Titan
Armata (NASDAQ: ARMP) director receives 25,640 stock options at $11.61 strike - Stock Titan
[Form 4] Armata Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Armata Pharmaceuticals (ARMP) grants director 25,640 stock options - Stock Titan
Armata Pharmaceuticals (ARMP) director receives grant of 25,640 stock options - Stock Titan
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Published on: 2026-03-08 06:18:18 - baoquankhu1.vn
Will Armata Pharmaceuticals Inc. stock return to pre crisis levelsNew Guidance & Risk Controlled Swing Alerts - Naître et grandir
New Strong Sell Stocks for April 24th - MSN
Will Armata Pharmaceuticals Inc. stock outperform growth indexesQuarterly Portfolio Summary & Verified Technical Trade Signals - Naître et grandir
ARMPAmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split - mx.advfn.com
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Yahoo Finance
Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX - RTTNews
ARMP Should I Buy - Intellectia AI
Armata Pharmaceuticals (ARMP) Price Target Increased by 25.00% to 15.30 - Nasdaq
H.C. Wainwright lowers Armata Pharmaceuticals stock price target to $15 By Investing.com - Investing.com Canada
ARMP: HC Wainwright & Co. Raises Price Target to $15 | ARMP Stoc - GuruFocus
Armata Pharmaceuticals (ARMP) Receives FDA Designation for AP-SA - GuruFocus
Armata Pharmaceuticals stock gains on FDA designation By Investing.com - Investing.com Canada
Armata Pharmaceuticals stock gains on FDA designation - Investing.com India
Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment - marketscreener.com
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy - TipRanks
Armata Pharmaceuticals receives FDA qualified infectious disease product designation - marketscreener.com
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation - TradingView
Armata Pharmaceuticals wins FDA QIDP for AP-SA02, enabling 5 years exclusivity and Fast Track eligibility - TradingView
FDA grants QIDP designation to Armata (ARMP) phage therapy AP-SA02 - Stock Titan
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PR Newswire
Growth Value: What analysts say about Armata Pharmaceuticals Inc stock2025 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Options Flow: Is HFBL a turnaround storyMarket Volume Report & AI Driven Stock Movement Reports - baoquankhu1.vn
ARMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Significant Increase in Short Interest - MarketBeat
Is Armata Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Drop Watch & Safe Investment Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
MACD Signal: What analysts say about Armata Pharmaceuticals Inc stockJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - baoquankhu1.vn
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):